Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021, 165(3):316-321 | DOI: 10.5507/bp.2020.017

Expression of cancer stem cells markers in urinary bladder urothelial carcinoma and its precursor lesions

Jaromir Haceka, Antonin Brisudab, Marek Babjukb, Josef Zamecnika
a Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
b Department of Urology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

Background: Cancer stem cells (CSC) and their role in tumorigenesis of various solid tumors have been studied in past decades. Urothelial CSC were first identified 10 years ago and subsequent studies have been performed with the aim to identify reliable markers of CSC. So far, a few studies have investigated a relationship between CSC markers expression in urothelial carcinoma tissue and histopathological characteristics of the tumor.

Methods: In our study, we evaluated an immunoexpression of the CSC markers CD24, CD44, CD66 and CD133 in tissue sections of urothelial carcinoma (all tumor grades and stages were included), urothelial carcinoma in situ and non-neoplastic urothelium, totally 218 specimens were enrolled.

Results: All studied molecules were expressed either in tumor tissue and non-neoplastic urothelium. Urothelial carcinomas of higher tumor grade and stage expressed molecules CD24 and CD133 significantly more frequently whereas molecules CD44 and CD66 did not show significant association with tumor histopathological features.

Conclusions: Our results showed that studied molecules are not suitable for direct detection of CSC in urothelial carcinoma tissue sections, but an expression of molecules CD24 and CD133 is significantly related to urothelial carcinoma grade and stage, which are both important prognostic indicators and therefore an expression of these markers might have a potential prognostic value.

Keywords: cancer stem cells, immunohistochemistry, markers, urothelial carcinoma

Received: January 24, 2020; Revised: April 6, 2020; Accepted: April 6, 2020; Prepublished online: May 18, 2020; Published: September 20, 2021  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Hacek, J., Brisuda, A., Babjuk, M., & Zamecnik, J. (2021). Expression of cancer stem cells markers in urinary bladder urothelial carcinoma and its precursor lesions. Biomedical papers, 165(3), 316-321. doi: 10.5507/bp.2020.017
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Moch H, Humphrey PA, Ulbright TM, Reuter V. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon, France: International Agency for Research on Cancer; 2016. Go to original source...
    2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34. Go to original source... Go to PubMed...
    3. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68. Go to original source... Go to PubMed...
    4. Kreso A, Dick JE. Evolution of the Cancer Stem Cell Model. Cell Stem Cell 2014;14:275-91. Go to original source... Go to PubMed...
    5. Dick JE. Stem cell concepts renew cancer research. Blood 2008;112:4793-807. Go to original source... Go to PubMed...
    6. Bokmen S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. Br J Cancer 2010;103:439-45. Go to original source... Go to PubMed...
    7. Fang D, Kitamura H. Cancer stem cells and epithelial-mesenchymal transition in urothelial carcinoma: Possible pathways and potential therapeutic approaches. Int J Urol 2018;25:7-17. Go to original source... Go to PubMed...
    8. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J Jr, Chang HY, van de Rijn M, Shortliffe L, Weissman IL. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009;106:14016-21. Go to original source... Go to PubMed...
    9. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: An enduring ambiguity. Clin Dev Immunol 2012;2012:708036. doi: 10.1155/2012/708036 Go to original source... Go to PubMed...
    10. Huang P, Watanabe M, Kaku H, Ueki H, Noguchi H, Sugimoto M, Hirata T, Yamada H, Takei K, Zheng S, Xu K, Nasu Y, Fujii Y, Liu C, Kumon H. Cancer stem cell-like characteristics of a CD133+ subpopulation in the J82 human bladder cancer cell line. Mol Clin Oncol 2013;1:180-4. Go to original source... Go to PubMed...
    11. Hofner T, Macher-Goeppinger S, Klein C, Schillert A, Eisen C, Wagner S, Rigo-Watermeier T, Baccelli I, Vogel V, Trumpp A, Sprick MR. Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy. Urol Oncol 2014;32:678-86. Go to original source... Go to PubMed...
    12. Li Y, Lin K, Yang Z, Han N, Quan X, Guo X, Li C. Bladder cancer stem cells: clonal origin and therapeutic perspectives. Oncotarget 2017;8:66668-79. Go to original source... Go to PubMed...
    13. Liu C, Zheng S, Shen H, Xu K, Chen J, Li H, Xu Y, Xu A, Chen B, Kaku H, Nasu Y, Kumon H, Huang P, Watanabe M. Clinical significance of CD24 as a predictor of bladder cancer recurrence. Oncol Lett 2013;6:96-100. Go to original source... Go to PubMed...
    14. Desai S, Lim SD, Jimenez RE, Chun T, Keane TE, McKenney JK, Zavala-Pompa A, Cohen C, Young RH, Amin MB. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol 2000;13:1315-23. Go to original source... Go to PubMed...
    15. Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 8th Edition. Oxford: Wiley-Blackwell; 2016. Go to original source...
    16. Soltanian S, Matin MM. Cancer stem cells and cancer therapy. Tumour Biol 2011;32:425-40. Go to original source... Go to PubMed...
    17. Farid RM, Sammour SA, Shehab ElDin ZA, Salman MI, Omran TI. Expression of CD133 and CD24 and their different phenotypes in urinary bladder carcinoma. Cancer Manag Res 2019;11:4677-90. Go to original source... Go to PubMed...
    18. Sedaghat S, Gheytanchi E, Asgari M, Roudi R, Keymoosi H, Madjd Z. Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas. Appl Immunohistochem Mol Morphol 2017;25:196-202. Go to original source... Go to PubMed...
    19. Lopez-Beltran A, Montironi R, Vidal A, Scarpelli M, Cheng L. Urothelial dysplasia of the bladder: diagnostic features and clinical significance. Anal Quant Cytopathol Histpathol 2013;35:121-9. Go to PubMed...
    20. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009;15:2258-64. Go to original source... Go to PubMed...
    21. Durko L, Wlodarski W, Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M, Hogendorf P, Strzelczyk J, Malecka-Panas E. Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis. Dis Markers 2017;2017:3276806. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content